Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of February 2026. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a periodic financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to a specific securities transaction.
| Metric | Value |
|---|---|
| Transaction Type | Disposal of American Depositary Shares (ADSs) |
| Instrument ISIN | US37733W2044 |
| Transaction Price | $59.1700 |
| Transaction Volume | 67,601.825 ADSs |
| Transaction Date | February 5, 2026 |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a personal transaction by Dr. Hal Barron, a Non-Executive Director, involving the re-allocation of funds within his GSK Executive Supplemental Savings Plan account.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a regulatory disclosure of a director's share disposal.
Investor Verification Checklist
- Verify the total shareholding of Dr. Hal Barron post-transaction to assess ongoing alignment with company interests.
- Confirm the market price of GSK ADSs on February 5, 2026, to validate the reported transaction price of $59.17.
- Review the company's most recent Form 20-F or quarterly report for actual financial performance metrics, as this filing does not contain them.